{"title": "PDF", "author": "PDF", "url": "https://health.alaska.gov/dhcs/Documents/pharmacy/Criteria/202209.%20Soliris_Ultomiris_criteria_2022v2.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "ALASKA MEDICAID Prior Authorization Criteria Soliris and Ultom iris are complement inhibitors indicated for the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH) and the treatment of adult and pediatric patients one month of age and older with atypical h emolytic uremic syndrome (aHUS) to inhibit complement -mediated thrombotic microangiopathy (TMA). Soliris is also indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti -acetylcholine receptor (AchR) antibody positi ve and the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are -4 1 month of age or older AND ; 2.Patient has a documented diagnosis of aHUS AND ; 3.Diagnosis of thrombocytopenic purpura (TTP) has been ruled out ( I.E., normal ADAMTS 13 activity) or a trial of plasma exchange did not result in clinical improvement AND ; 4.Patient does not have a Shiga toxin -producing escherichia coli (E. coli) infection AND ; 5.Documented baseline values for one or more 1.Patient is 1 month of age or older AND ; 2.Patient has a documented diagnosis of PNH confirmed by flow cytometry diagnostic testing AND ; 3.Patient has one of the following indications for therapy: a.Presence of a thrombotic event b.Presence of organ damage secondary to chronic hemolysis c.Patient is pregnant and potential benefit outweighs poten tial fetal risk d.Patient is transfusion dependent e.Patient has high LDH activity (defined as 1.5 x ULN) with clinical symptoms AND ; 4.Patient has documented baseline values for all the following: ) 1. Patient is 18 years of age or older AND ; 2. Patient has a documented diagnosis of gMG with a Myasthenia Gravis Foundation of America (MGFA)clinical classification of II,III, or IV AND ; 3. Patient has Myasthenia Gravis -Specific Activities of Daily Living (MG -ADL) total score of 6 AND ; 4. Patient has a positive serologic test for anti -acetylcholine receptor (AchR) antibodies AND ; 5. Prescriber has assessed the baseline Quantitative Myasthenia Gravis (QMG) score AND ; 6. Documentation of inadequate response to or has a labeled contraindication to TWO or more immunosuppressive drug agents used alone or in combination for at least 12 months (I.E. azathioprine, mycophenolate mofetil, cyclosporine, cyclophosphamide, methotrexate, tacrolimus, rituximab) OR documentation of inadequate response to or has a labeled contraindication to ONE or more immunosuppressive drug agents as monotherapy or in combination therapy and requires chronic plasma exchange, plasmapheresis or intravenous immunoglobulin (Soliris only ) 1. Patient is 18 years of age or older AND ; 2. Patient has a documented diagnosis of NMOSD confirmed by a positive serologic test for anti-aquaporin -4 immunoglobulin G (AQP4 -IgG)/NMP -IgG antibodies AND ; 3. Documentation of failure or inadequate response [history of at least one relapse (acute attack from neuromyelitis spectrum disorder) in the last 12 months, or two relapses in the last 2 years] to ONE of the following systemic therapies; OR a Contraindicati on per FDA label or significant intolerance to ALL the following systemic therapies: . a. Azathioprine b. Mycophenolate c. Rituximab AND ; 4. The diagnosis of multiple sclerosis has been ruled out. DENIAL CRITERIA 1,2 1. Failure to meet approval criteria OR; 2. Patient has not had a vaccination against Neisseria meningitides at leas t 2 weeks prior to initiation OR; 3. Not being prescribed by or in consultation with a hematologist, nephrologist, or neurologist OR; 4. Prescriber is not enrolled in the REMS program package insert for cautions: Initial Approval: up to 4 months Reauthorization Approval: up to 12 months if the prescriber documents the patient has disease improvement QUANTITY LIMIT1,2 Soliris max dose = 1200mg Soliris J1300 Ultomiris J1303 [package JT, Beutel G, Fleig S, et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga -toxin -producing E. coli O104:H4 induced analysis of the German STEC -HUS registry. Nephrol Dial Transplant. 2012 Oct;27(10):3807 -15. 4. Campistol JM, Arias M, Ariceta G, An upd ate for atypical haemolytic uraemic syndrome: diagnosis and treatment. 5. Franchini M. Atypical hemolytic uremic syndrome: diagnosis to treatment. Clin Chem Lab Med. 2015 Oct;53(11):1679 - 88. 6. Sutherland DR, Keeney M, Illingworth A. Practical guidelines for the high -sensitivity detection and monitoring of paroxysmal nocturnal hemoglobinuria clones cytometry. -208. 7. Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti - acetylcholine receptor antibody positive refractory generalised myasthenia gravis al. A randomized, double -blind, placebo -controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Jul;48(1):76 -84. Neuromyelitis Optica Spectrum Disorder. Med. May 3 . 10. Nikoo Z, Badihian S, Shaygannejad V, et al. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis "}